News and Media

Aussie biotech aims high in race to cure cancer

Every year 45,000 of the most respected professionals in oncology gather at the American Society of Clinical Oncology (ASCO) annual ...
Read More
| News

Aussie biotech aims high in race to cure cancer

Every year 45,000 of the most respected professionals in oncology gather at the American Society of Clinical Oncology (ASCO) annual ...
Read More
| News

The biggest breakthrough in cancer research since chemotherapy

Last month, the best and brightest minds in oncology gathered (virtually) for the American Society of Clinical Oncology (ASCO) annual ...
Read More
| News

Prescient Therapeutics’ (ASX:PTX) assets selected for COVID-19 antiviral trial

Two of Prescient Therapeutics' (PTX) assets have been handpicked for a COVID-19 antiviral testing program. The trial, run by the ...
Read More
| News

Two of Prescient’s Assets Selected for COVID-19 Antiviral Testing Program, Stock up ~18%

Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and Immunology subsequent to the selection ...
Read More
| News

Receive Email Updates

To stay fully updated on Prescient Therapeutics Corporate Activity and Company Announcements, please subscribe for up to the minute updates

WEBCAST AND MEDIA

PTX Shareholder Briefing - 4 August

PTX CEO Steven Yatomi Clarke discusses Prescient Therapeutics treatments in detail

Follow us and stay connected